Literature DB >> 7979306

Activity of clinafloxacin against multidrug-resistant Enterococcus faecium.

S Burney1, D Landman, J M Quale.   

Abstract

Enterococci resistant to ampicillin, vancomycin, and/or aminoglycosides are a growing clinical problem. We studied the in vitro activity of the new fluoroquinolone clinafloxacin (PD 127,391) against 15 clinical isolates of multidrug-resistant Enterococcus faecium. In kill-kinetic studies, clinafloxacin (1 microgram/ml) was bactericidal against 7 of 12 susceptible isolates, although substantial regrowth occurred in 4 isolates at 48 h. The addition of ampicillin (20 micrograms/ml) resulted in bactericidal activity in all 12 isolates, and no regrowth was seen. For three isolates resistant to clinafloxacin, effective killing was not observed at these concentrations of antibiotics. Clinafloxacin with ampicillin shows promising activity against many of these multiply resistant enterococci.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7979306      PMCID: PMC284614          DOI: 10.1128/AAC.38.7.1668

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Increasing resistance of enterococci to ciprofloxacin.

Authors:  D R Schaberg; W I Dillon; M S Terpenning; K A Robinson; S F Bradley; C A Kauffman
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

2.  Identification of Enterococcus species isolated from human infections by a conventional test scheme.

Authors:  R R Facklam; M D Collins
Journal:  J Clin Microbiol       Date:  1989-04       Impact factor: 5.948

3.  A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit.

Authors:  L V Karanfil; M Murphy; A Josephson; R Gaynes; L Mandel; B C Hill; J M Swenson
Journal:  Infect Control Hosp Epidemiol       Date:  1992-04       Impact factor: 3.254

4.  Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers.

Authors:  L L Livornese; S Dias; C Samel; B Romanowski; S Taylor; P May; P Pitsakis; G Woods; D Kaye; M E Levison
Journal:  Ann Intern Med       Date:  1992-07-15       Impact factor: 25.391

5.  Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin.

Authors:  S Handwerger; B Raucher; D Altarac; J Monka; S Marchione; K V Singh; B E Murray; J Wolff; B Walters
Journal:  Clin Infect Dis       Date:  1993-06       Impact factor: 9.079

6.  Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.

Authors:  D Shonekan; D Mildvan; S Handwerger
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

7.  Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium.

Authors:  M S Whitman; P G Pitsakis; A Zausner; L L Livornese; A J Osborne; C C Johnson; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

8.  Comparative in vitro activity of PD 127,391, a new fluorinated 4-quinolone derivative.

Authors:  S R Norrby; M Jonsson
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

9.  In vitro activities of quinolones against enterococci resistant to penicillin-aminoglycoside synergy.

Authors:  D F Sahm; G T Koburov
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

10.  In vitro and in vivo activity of ciprofloxacin against enterococci isolated from patients with infective endocarditis.

Authors:  M Fernandez-Guerrero; M S Rouse; N K Henry; J E Geraci; W R Wilson
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

View more
  4 in total

Review 1.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 2.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

3.  In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium.

Authors:  R C Mercier; S R Penzak; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

4.  In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci.

Authors:  M A Cohen; S L Yoder; M D Huband; G E Roland; C L Courtney
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.